Jove
Visualize
Contact Us

Related Experiment Video

Updated: Jun 24, 2026

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

Recurrence Rates of Incompletely Excised Primary Basal Cell Carcinoma Treated With Mohs Micrographic Surgery and

Georgia De'Ambrosis1,2, Brian De'Ambrosis1,2, Perry Wilson3

  • 1South East Dermatology, Brisbane, Queensland, Australia.

The Australasian Journal of Dermatology
|June 23, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab in the Treatment of Cutaneous Lymphoid Hyperplasia.

The Australasian journal of dermatology·2026
Same author

Misleading Hepatitis B Serology Following Intravenous Immunoglobulin Treatment for Pemphigus Vulgaris.

The Australasian journal of dermatology·2025
Same author

Germline and somatic albinism variants in amelanotic/hypomelanotic melanoma: Increased carriage of TYR and OCA2 variants.

PloS one·2020
Same author

Cluster of pregnancy-associated melanoma: A case report and brief update.

The Journal of dermatology·2020
Same author

The interplay of sun damage and genetic risk in Australian multiple and single primary melanoma cases and controls.

The British journal of dermatology·2019
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Mohs micrographic surgery (MMS) shows no recurrence for incompletely excised primary basal cell carcinoma (pBCC) over 9 years. Adjuvant radiotherapy (PORT) is effective for high-risk pBCC cases managed with MMS.

Area of Science:

  • Dermatology
  • Surgical Oncology
  • Oncology

Background:

  • Incompletely excised primary basal cell carcinoma (pBCC) management is not well-defined.
  • Recurrence rates after Mohs micrographic surgery (MMS) for re-excised pBCC are under-documented.

Purpose of the Study:

  • To evaluate the recurrence rates of incompletely excised pBCCs treated with MMS.
  • To assess the efficacy of adjuvant post-operative radiotherapy (PORT) in high-risk cases.

Main Methods:

  • Retrospective cohort study of patients undergoing re-excision with MMS for pBCC.
  • Minimum 5-year follow-up period post-definitive treatment.
  • Data collected from private practices in Queensland, Australia.

Main Results:

Keywords:
Mohs surgerybasal cell carcinomasurgical margins

Related Experiment Videos

Last Updated: Jun 24, 2026

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

  • 104 patients with incompletely excised pBCCs treated with MMS showed no recurrence over a mean follow-up of 9.2 years.
  • 92.1% of cases involved aggressive basal cell carcinoma subtypes.
  • 51.9% of cases were in high-risk anatomical locations; 11.5% had perineural invasion.

Conclusions:

  • MMS appears effective for managing incompletely excised pBCC in immunocompetent patients.
  • PORT is an effective adjuvant therapy when combined with MMS for high-risk pBCC.
  • Further prospective studies are needed to explore MMS for recurrent and non-surgically treated BCCs.